The kappa-opioid receptor/dynorphin system has long been understood as a kind of counterweight to the mu-opioid receptor system. Where mu-opioid stimulation produces the euphoria and addictive pull of drugs like morphine, kappa-opioid activation produces dysphoria, aversion and negative emotional states. Animal studies have repeatedly shown that blocking the receptor with antagonists such as norbinaltorphimine or JDTic produces anxiolytic and antidepressant-like effects, while activating it induces the opposite. Yet the review emphasizes that this simple picture conceals a far more complicated reality. In some circumstances kappa-opioid stimulation can actually be rewarding, and mice engineered to lack the receptor throughout the central nervous system do not uniformly show reduced anxiety. The receptor couples to multiple downstream signalling pathways with different outcomes, and different ligands can preferentially engage some of those pathways over others. Even more surprisingly, while the receptor normally couples to inhibitory Gi proteins and hyperpolarizes neurons, under certain conditions it can switch to Gs coupling and depolarize them instead.

To untangle this complexity, the review organizes the evidence around two major brain circuits. The first is the prefrontal cortex-hippocampus-amygdala circuit, central to fear learning, fear extinction and anxiety. The second is the ventral tegmental area-nucleus accumbens pathway, the brain’s principal reward machinery. Both are heavily implicated in major depressive disorder and anxiety disorders, and both are richly endowed with kappa-opioid receptors whose distribution, cellular targets and behavioural roles differ markedly from region to region.

Within the prefrontal cortex, the review highlights a striking degree of circuit specificity. In rodents, dynorphin-expressing neurons are found in the infralimbic cortex, in both somatostatin-positive inhibitory interneurons and glutamatergic projection cells. Notably, the rodent medial prefrontal cortex contains a higher proportion of somatostatin-positive than parvalbumin-positive interneurons, suggesting the kappa system carries particular weight in this region. Stimulating the receptor in the prelimbic cortex produces place aversion, and agonist administration into the medial prefrontal cortex silences potentials evoked by basolateral amygdala inputs. Recent work suggests the system acts as a kind of switching mechanism: by inhibiting kappa-positive neurons and certain interneuron classes, it can selectively amplify signals arriving from kappa-negative projections, such as those from the ventral hippocampus, effectively re-weighting the importance of competing information streams during threat processing.

The hippocampus tells its own story. The dentate gyrus holds the highest density of dynorphin and kappa-opioid receptors in the structure, and stressful events increase hippocampal dynorphin expression, with sudden surges associated with reduced synaptic transmission and prolonged suppression of long-term potentiation at key synapses. In the Wistar-Kyoto rat, a genetic model of depression, prodynorphin mRNA peaks in the dentate gyrus, and direct injection of the antagonist norbinaltorphimine into the CA3 region produces antidepressant effects in a learned helplessness paradigm. The system also intersects with brain-derived neurotrophic factor, a molecule central to synaptic plasticity and antidepressant action: blocking kappa receptors raises hippocampal BDNF expression, while the agonist U50488 suppresses it and worsens depressive symptoms in mice. Standard antidepressants including imipramine, fluoxetine and citalopram can counteract the agonist-induced BDNF reduction in the hippocampus, though not in the prefrontal cortex.

In the amygdala, the receptor’s role in fear memory is particularly vivid. Fear conditioning upregulates kappa-opioid receptors in the basolateral amygdala, and successful fear extinction brings expression back down. Infusing the antagonist JDTic into the basolateral and central amygdala reduces fear expression, while basolateral infusion alone is anxiolytic. The agonist U50488 increases the activity of basolateral pyramidal neurons through a MAPK-pathway-dependent mechanism, likely by inhibiting local inhibitory interneurons, and presynaptic receptors on basolateral outputs dampen glutamatergic signalling to both the nucleus accumbens and the prefrontal cortex. The system also ties directly into the stress axis: blocking kappa receptors in the basolateral amygdala counteracts the anxiogenic effects of corticotropin-releasing factor, which appears to activate the dynorphin machinery through its type 1 receptor. Within the central amygdala, a subset of CRF-producing inhibitory neurons releases GABA under baseline conditions to restrain anxiety, but under aversive conditions they co-release dynorphin and CRF, tipping the balance toward fear and aversion.

The reward circuitry of the ventral tegmental area and nucleus accumbens adds another layer. In the ventral tegmental area, kappa receptors sit presynaptically on dopaminergic neurons, and acute stress disrupts a nitric-oxide-mediated feedback loop that normally restrains dopamine firing. Under stress, constitutive receptor activation silences the inhibitory GABAergic neurons, allowing dopaminergic neurons to fire more rapidly, an effect reversed by norbinaltorphimine. In the nucleus accumbens, the two principal medium spiny neuron populations express different opioid peptides: dynorphin in reward-processing D1 neurons, enkephalins in aversion-processing D2 neurons. Depression models show that blocking kappa receptors directly in the accumbens alleviates depressive behaviour, and inhibiting CREB, the transcription factor that upregulates prodynorphin there, produces similar benefit. In a morphine-withdrawal model of depression, microdoses of antagonist injected into the accumbens were antidepressant, and chronic systemic administration extended the effect for up to two weeks.

Human evidence, though sparser, is strikingly consistent with the animal work. Postmortem studies find reduced prodynorphin mRNA in the amygdala of individuals with major depressive disorder, particularly in its parvicellular and magnocellular divisions and the amygdalohippocampal area, and a similar reduction in the periamygdaloid cortex of heroin users, a shared molecular signature linking addiction and depression through the same circuitry. In rhesus macaques, the kappa antagonist navacaprant protects against stress-induced working memory impairments, apparently by interfering with receptor-modulated norepinephrine and dopamine release in the prefrontal cortex. Depressed patients, meanwhile, require greater prefrontal activation than healthy controls to achieve comparable task performance, hinting at the circuit-level inefficiency that kappa-directed drugs might help relieve.

The review is candid about the field’s limitations. Most evidence comes from rodent studies that frequently neglect sex, age and social status, variables that demonstrably matter. Depression is more prevalent in females, oestrogen signalling can regulate kappa/mu receptor heterodimer formation, and sex-dependent differences in receptor localization and function have been reported in both rodents and humans. Adolescent rodents respond differently to kappa manipulation than adults, and in non-human primates receptor availability varies with social rank. Human imaging faces its own constraints: functional MRI offers only indirect measures of neuronal activity, while positron emission tomography with kappa-selective radiotracers is limited by cost, radiation exposure and small samples. These gaps explain why optogenetics, chemogenetics and electrophysiology in animals remain indispensable, even as they cannot fully reproduce the subjective texture of human affective illness.

What emerges is a system far richer than a simple molecular brake on mood. The kappa-opioid receptor/dynorphin system acts differently in each node of these circuits, on different cell types, at different developmental stages and under different hormonal and social conditions, sometimes inhibiting and sometimes, paradoxically, exciting. That complexity is precisely what makes it therapeutically interesting: rather than globally suppressing or enhancing a neurotransmitter, kappa-directed drugs could in principle retune specific switches within the fear and reward circuitry. As clinical trials of kappa antagonists progress, the review argues, future studies must build sex, age and social context into their designs from the start, because the same receptor that drives dysphoria in one context may hold the key to resilience in another.

Subject of Research: The role of the kappa-opioid receptor/dynorphin system in modulating prefrontal-hippocampal-amygdala and mesolimbic circuits involved in depression and anxiety

Article Title: The Role of Kappa‐Opioid Receptor/Dynorphin System in Modulating Neural‐Circuits of Depression and Anxiety—A Review

Article References: Ciotei, C., Păunescu, H., Lungu, C., Marica, A.-A., Tănase, M. F., Marin, R.-C., Costescu, M., Fulga, I., & Coman, O. A. (2026). The Role of Kappa‐Opioid Receptor/Dynorphin System in Modulating Neural‐Circuits of Depression and Anxiety—A Review. Journal of Cellular and Molecular Medicine, 30(19), Article e71392. https://doi.org/10.1111/jcmm.71392

Image Credits: AI Generated

DOI: 10.1111/jcmm.71392

Keywords: kappa-opioid receptor, dynorphin, depression, anxiety, amygdala, nucleus accumbens, ventral tegmental area, prefrontal cortex, hippocampus, KOR antagonists, neural circuits, BDNF

The research, led by Yinan Li and colleagues at Kyoto University together with collaborators in Japan and China, tackled the problem by mapping the functional wiring between the dopaminergic midbrain and the striatum in a large sample of 116 patients with schizophrenia and 224 age- and sex-matched healthy controls. All participants underwent resting-state functional magnetic resonance imaging, a technique that measures spontaneous fluctuations in blood-oxygen-level-dependent signal while people simply lie still in the scanner. The team then computed functional connectivity between six subdivisions of the striatum—limbic, executive, and sensorimotor regions in each hemisphere—and individual voxels within the ventral tegmental area and substantia nigra, the two midbrain structures that house the brain’s dopamine-producing neurons.

The technical rigor behind this mapping deserves attention, because the midbrain is one of the hardest structures in the brain to image reliably. The ventral tegmental area and substantia nigra are small, densely packed nuclei, and their signals are easily contaminated by head motion, physiological noise, and susceptibility distortions. The researchers deployed an unusually comprehensive denoising pipeline combining FSL, FreeSurfer, and independent component analysis-based cleanup, used midbrain masks anatomically optimized for East Asian brains, harmonized data from two different 3-Tesla scanners with the ComBat statistical procedure, and deliberately avoided global signal regression to prevent artificial negative correlations from contaminating their connectivity gradients. Sensitivity analyses with different smoothing parameters confirmed that the results were robust.

The first major finding was a confirmation, for the first time in humans, of the canonical ventral-to-dorsal organization of the midbrain-striatal dopamine system. In animal work, tracing studies have shown that the ventral midbrain preferentially projects to the ventral striatum while more dorsal midbrain regions project to dorsal striatal territories. To test whether this holds in living humans, the team split the midbrain mask along two orthogonal axes—inferior versus superior and anterior versus posterior—and counted, for each striatal seed, the proportion of positively connected voxels falling in each half. Using beta regression, a statistical approach well suited to proportional data, they found that these bias measures declined linearly along both axes with extraordinary statistical significance, demonstrating that the ventral limbic striatum couples preferentially to the anterior and inferior midbrain, with progressively more dorsal striatal regions shifting their coupling posteriorly and superiorly.

With the map established, the team turned to the clinical question. When they compared diagnostic groups, they found that patients with schizophrenia showed significantly reduced functional connectivity between the left anterior midbrain and the left ventral limbic striatum—the classic mesolimbic pathway. This hypoconnectivity is consistent with a substantial body of prior resting-state imaging work in chronic schizophrenia, first-episode psychosis, and individuals at clinical high risk, and it persisted even after the researchers statistically controlled for antipsychotic medication doses, illness duration, education, premorbid intelligence, and smoking status. Notably, however, this ventral-limbic reduction did not correlate with the severity of any symptom domain measured by the Positive and Negative Syndrome Scale.

The pivotal discovery emerged when the researchers brought in the Aberrant Salience Inventory, a 29-item questionnaire that captures subjective experiences of aberrant salience, such as whether trivial things suddenly seem especially significant or whether one’s senses seem unusually sharpened. Drawing on a recently validated three-subscale model, they separated motivational salience, cognitive salience, and sensory salience, and tested how each interacted with diagnosis to shape midbrain-striatal connectivity. The striking result was a significant interaction involving the sensory salience subscale—the so-called Sharpening of Senses dimension—specifically for the connection between the left anteroinferior midbrain, corresponding to the lateral ventral tegmental area and ventromedial substantia nigra, and the left dorsal sensorimotor striatum. Not the ventral striatum. The dorsal one.

The nature of this interaction was as revealing as its location. In healthy controls, higher sensory salience scores were associated with stronger positive coupling between the ventral midbrain and the dorsal sensorimotor striatum, suggesting that in the healthy brain this circuit supports the adaptive, coordinated assignment of significance to sensory events. In patients with schizophrenia, the relationship reversed: higher sensory salience scores were associated with weaker, even negative coupling. This crossover pattern indicates not a simple amplification or dampening of the salience circuit, but a pathological desynchronization—a breakdown of the normal coordinated dynamics through which dopaminergic signals and striatal sensorimotor processing work in tandem. The researchers interpret this as the circuit-level signature of ordinary perceptions acquiring abnormal, personally meaningful significance, a process that can ultimately feed hallucinations and delusions.

Several additional analyses strengthened the claim that this finding is genuinely about aberrant salience rather than general psychiatric illness. The sensory salience subscale correlated significantly with positive symptoms, general psychopathology, and total symptom scores in patients. More compellingly, hierarchical regression showed that the subscale remained a robust independent predictor of midbrain-dorsal striatal connectivity even after controlling for these symptom measures, explaining an additional 17 to 24 percent of the variance in connectivity. In other words, the dysconnectivity tracked the subjective experience of aberrant salience more closely than it tracked overt symptom severity. The authors are careful to note, however, that the connectivity measure itself did not correlate directly with positive symptom scores, positioning it as a neural correlate of aberrant salience rather than of psychosis per se—a distinction that reflects the multifactorial nature of psychotic symptoms.

The broader significance of the study lies in how it reconciles a long-standing contradiction. Animal research has historically emphasized the ventral midbrain-to-ventral striatum pathway in dopamine dysregulation, while human positron-emission tomography studies have repeatedly found elevated dopamine synthesis capacity in the dorsal associative and sensorimotor striata of patients, not the ventral limbic striatum. By showing that the relevant circuit in humans runs from the ventral midbrain to the dorsal sensorimotor striatum—a projection pattern that animal tracer studies had actually documented but that human work had not previously linked to salience—the new findings bridge the two literatures. They also highlight an anatomical subtlety: unlike the strictly parallel corticostriatal system, the dopaminergic midbrain-striatal pathway includes overlapping, spiraling connections across the ventral-to-dorsal axis, and the rotation of the brain between quadrupedal animals and bipedal humans complicates any simple translation of ventral and dorsal labels across species.

The study is not without limitations. All patients were taking antipsychotic medication, which cannot be fully ruled out as a contributor despite the statistical controls; the blood-oxygen-level-dependent signal reflects a mixture of dopaminergic and GABAergic activity rather than dopamine alone; and the salience questionnaire was available for a subset of participants, 38 patients and 74 controls, which may have limited statistical power for the interaction analyses. Even so, the combination of a large overall sample, meticulous denoising, scanner harmonization, species-optimized midbrain masks, and converging sensitivity analyses makes this one of the most convincing demonstrations to date of where aberrant salience lives in the human brain. If replicated, the ventral midbrain-dorsal sensorimotor striatal circuit could serve as an imaging biomarker for aberrant salience, potentially enabling earlier identification of people at risk for psychosis and offering a more precise target for interventions aimed at quieting the brain’s tendency to shout meaning where there is none.

Subject of Research: Midbrain-striatal functional connectivity and aberrant salience in schizophrenia

Article Title: Aberrant salience is selectively associated with ventral midbrain connectivity to the dorsal but not ventral striatum

Article References: Li, Y., Oishi, N., Dai, Q., Nakagami, Y., Yao, L., Kawashima, T., Yoshihara, Y., Kubota, M., Nakamura, Y., Koike, S., Murai, T., & Miyata, J. (2026). Aberrant salience is selectively associated with ventral midbrain connectivity to the dorsal but not ventral striatum. Schizophrenia, 12(1), Article 71. https://doi.org/10.1038/s41537-026-00795-2

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00795-2

Keywords: schizophrenia, aberrant salience, dopamine, ventral tegmental area, substantia nigra, striatum, resting-state fMRI, functional connectivity, psychosis, delusions, hallucinations, sensorimotor striatum

The research focused on the ventral tegmental area, a midbrain region long associated with reward, motivation and goal-directed behavior. Within this region sits a population of dopamine neurons that is activated when mothers interact with their pups and that supports the motivated behaviors underlying maternal care. Because these cells sit at the intersection of motivation and parenting, the team reasoned that scarcity-adversity during the postpartum period might reshape how they respond to pup-related cues. To test this, the researchers compared mothers given sufficient bedding to build nests with mothers given limited nesting resources, a well-established rodent model of postpartum adversity that reliably degrades the quality of maternal care.

The results were striking in their specificity. In mothers exposed to resource scarcity, neural activity in this population rose before and during episodes of harmful treatment of pups, a pattern the researchers describe as a maladaptive brain signature. When the same mothers were separated from their pups, activity in these neurons dropped below the levels observed in mothers with adequate nesting materials. In other words, the scarcity experience did not simply dampen or amplify the circuit uniformly; it reorganized when and how the neurons fired depending on the caregiving context.

Rincón-Cortés acknowledged that the outcome defied the team’s expectations. The researchers had predicted that the neurons would show altered activity when mothers were expressing adequate maternal care toward their pups, but that did not happen. Instead, increased activity appeared only right before and during insensitive behavior toward the young. This timing matters, because it suggests the neural changes are not a general feature of scarcity-exposed mothers but are tied to the specific moments when caregiving breaks down. The activity pattern, she noted, seems to be a maladaptive brain signature rather than a marker of normal maternal behavior.

To probe whether the effect extended beyond parenting, the team examined how scarcity-exposed mothers responded to a different kind of motivated behavior: receiving a food reward. Because the ventral tegmental area dopamine population is involved in general motivation, the researchers asked whether mothers with fewer nesting resources would show altered activity when food was delivered. They found no differences compared with mothers that had adequate nesting resources. The absence of a food-reward effect indicates that the neural changes are specific to the maternal caregiving context rather than reflecting a broad disruption of motivational processing across all rewarding situations.

That specificity carries an important conceptual message about how stress affects the brain. Stress and adversity are often thought to turn down activity in these dopamine cells, but the new findings suggest the picture is not that simple. As Rincón-Cortés explained, context matters, and how these neurons respond depends on what the mother is doing. A circuit that looks suppressed during pup separation may look abnormally active during insensitive caregiving, and may look entirely normal during non-parental reward tasks. For scientists studying postpartum mental health, this argues against one-size-fits-all models of stress-induced neural change and favors accounts that track behavior in real time.

The work also helps connect a widely used animal model to a pressing human problem. Limited bedding paradigms in rodents are designed to mimic the experience of parents who lack the material means to provide adequate care, a form of adversity that epidemiological studies have linked to impaired caregiving, harsh parenting and elevated risk of postpartum depression. By identifying a neural population whose activity diverges precisely during harmful pup-directed behavior, the study provides a candidate mechanism linking environmental deprivation to caregiving quality. The dopamine system’s role in motivation offers a plausible logic: if scarcity reshapes how motivation circuits respond to pups, the drive to nurture may be distorted in ways that manifest as neglect or harm.

According to the authors, the research reveals how a lack of resources shapes the activity of this neuron population in mother rats in ways that hinder caregiving. The study, titled Ventral Tegmental Area Dopamine Neuron Dynamics During Postpartum Scarcity-Adversity Depend on Caregiving Quality and Pup Proximity, was published on 5 October 2026, and the authors declared no competing financial interests. The emphasis on pup proximity in the study’s framing underscores a central technical point: neural dynamics in these mothers depended jointly on caregiving quality and on how close the mothers were to their pups, reinforcing the idea that parenting circuits are continuously modulated by the immediate social and material environment.

The research team has several projects planned that build on these findings. One effort will use a machine learning approach to identify patterns of behavior that can predict abuse toward pups, potentially turning rich behavioral recordings into early-warning signals before harm occurs. Another line of investigation will explore whether government-approved treatments can either prevent the maladaptive brain change from occurring in resource-scarce rats or reverse the altered brain activity after scarcity has taken its toll. Such translational steps would test whether the neural signature identified in this study is not just a correlate of poor caregiving but a targetable mechanism.

For a field seeking to understand how poverty, deprivation and material hardship get under the skin to affect parenting, the study offers both a caution and a lead. The caution is that adversity does not produce a single, uniform neural state; the same circuit can be quiet in one context and overactive in another, so measurements must be anchored to specific behaviors. The lead is that a well-characterized motivation circuit, accessible to recording in animal models and responsive to the caregiving environment, shows a distinctive and behaviorally timed signature when care goes wrong. If future work can prevent or reverse that signature, the findings could inform interventions aimed at protecting both mothers and their children from the consequences of raising a family without adequate resources.

Subject of Research: How postpartum resource scarcity alters ventral tegmental area dopamine neuron activity and maternal caregiving behavior in rats

Article Title: Resource scarcity influences maternal brain activity and caregiving in rats

Article References: Resource scarcity influences maternal brain activity and caregiving in rats. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuroscience, maternal behavior, dopamine neurons, ventral tegmental area, resource scarcity, postpartum depression, rat model, caregiving, stress adversity, JNeurosci, motivation, pup-directed behavior

The research, led by Qianru Zhao, Bing Feng, and Vicky Dong of the Pennington Biomedical Research Center at Louisiana State University, together with colleagues at Baylor College of Medicine, the University of Illinois Chicago, Tulane University, Nanyang Technological University, and South-Central Minzu University, set out to answer a question that has puzzled neuroscientists for years. Pregnancy is known to reshape appetite—rodents eat more as gestation advances, and human studies have documented heightened craving frequency, emotional eating, and excess gestational weight gain. Yet while hypothalamic circuits governing hunger have been mapped in detail, the mechanisms behind the selective, sometimes obsessive desire for palatable foods during pregnancy remained largely unexplored at the level of individual neurons and their ion channels.

The team began by characterizing the behavior itself. Using the BioDAQ automated feeding-monitoring system, they gave female mice intermittent access to highly palatable diets—a high-fat diet, a high-protein diet, and a high-sucrose diet—and measured not just how much the animals ate but how hard they worked to seek food when it was inaccessible. On day fourteen of gestation, a stage comparable to the second trimester in humans, pregnant mice showed a striking escalation in craving-like behavior. They consumed larger meals of the palatable diets more frequently, spent more time probing the food hopper when food was withheld, and lingered longer in the hopper zone, all while their intake of ordinary chow and their body-weight gain remained comparable to those of virgin controls. The pattern, the authors note, echoes many of the behavioral signatures described in human pregnancy studies, from increased craving frequency to the dissociation between craving and caloric need.

With the behavioral phenotype established, the researchers turned to the brain. The dorsal raphe nucleus, a narrow ridge of cells along the brainstem’s midline, supplies the bulk of the brain’s serotonin, a neurotransmitter long implicated in mood, appetite, and reward. Using whole-cell patch-clamp electrophysiology, the team recorded from fluorescently identified serotonin neurons in the dorsal raphe of virgin mice and pregnant mice at gestational day fourteen. The result was unambiguous: serotonin neurons from pregnant animals fired action potentials at significantly lower frequencies than those from virgin animals, and their resting membrane potentials reflected a hyperpolarized, less excitable state. Notably, the suppression persisted into the postpartum period, hinting that the change is not a fleeting response to a single hormonal moment but a sustained rewiring of the cell’s electrical properties.

To understand why the neurons fell silent, the investigators turned to single-cell transcriptomics. Patch-seq analysis, which combines electrophysiological recording with single-cell RNA sequencing, revealed a molecular shift in the serotonin neurons of pregnant mice: increased expression of the gene encoding the small-conductance calcium-activated potassium channel type 3, or SK3. These channels open in response to calcium influx during action potentials, allowing potassium ions to flow out of the cell and clamping the membrane back toward its resting potential. More SK3 current means each spike is followed by a stronger repolarizing brake, effectively throttling the neuron’s firing rate. The team confirmed the upregulation at the protein level, showing stronger SK3 immunofluorescence in serotonin neurons of pregnant animals, and measured larger apamin-sensitive SK currents—the pharmacological fingerprint of SK3 activity—in recordings from pregnant mice.

The causal test followed. When the researchers genetically deleted SK3 channels selectively from dorsal raphe serotonin neurons, two things happened. First, the pregnancy-associated suppression of firing frequency vanished; the neurons of pregnant mice lacking SK3 fired as briskly as those of virgins. Second, and more strikingly, the food-craving-like behavior of the pregnant animals dropped. Mice without SK3 in their serotonin neurons no longer showed the exaggerated seeking, consumption, and hopper-directed persistence of their pregnant wild-type counterparts. The implication is direct: the quieting of serotonin neurons, mediated by SK3, is not a byproduct of pregnancy cravings but a driver of them.

The converse experiment sealed the argument. In virgin female mice—animals that would not normally crave—the team overexpressed SK3 in dorsal raphe serotonin neurons using viral vectors. The manipulation suppressed neuronal firing and, remarkably, reproduced the pregnancy phenotype in animals that had never been pregnant. These virgin mice began to eat more palatable food, seek it more often, and spend more time at the hopper, mimicking the behavior of gestational-day-fourteen dams. A single ion channel, in a single population of brainstem neurons, was sufficient to install a craving-like state in a non-pregnant brain.

But where do these serotonin neurons act to change behavior? The answer pointed to the mesolimbic reward system. Anatomical tracing and optogenetic experiments showed that dorsal raphe serotonin neurons send monosynaptic projections to the ventral tegmental area, the hub of the brain’s dopamine reward circuitry. When the team activated this DRN-to-VTA pathway with channelrhodopsin, food-craving-like behavior in female mice diminished; when they inhibited the projection with halorhodopsin, the behavior was modulated in the opposite direction. Chemogenetic activation of the same circuit in pregnant mice reduced their craving for palatable diets. Intriguingly, stimulating serotonin terminals in the nucleus accumbens or lateral hypothalamus—two other major serotonin projection targets—failed to alter craving behavior, sharpening the picture of a circuit specifically routed through the ventral tegmental area. The emerging model is elegant: during pregnancy, SK3 channels silence serotonin neurons, releasing their inhibitory grip on the VTA’s reward machinery and thereby amplifying the motivational pull of palatable food.

The findings arrive at a moment of growing clinical concern about gestational weight gain. Prior research has shown that food-craving frequency during pregnancy mediates the relationship between emotional eating and excess weight gain, and that accumbal dopaminergic circuits mediate craving-like episodes in pregnant mice—work from a 2022 Nature Metabolism study that the present results build upon and extend by identifying an upstream serotonergic control point. Excessive gestational weight gain is associated with maternal obesity, gestational diabetes, and long-term metabolic risk for both mother and child, yet safe and effective interventions remain scarce. By pinpointing SK3 channels in dorsal raphe serotonin neurons as a molecular switch, the study offers a concrete pharmacological target. SK channels are already the focus of drug-development efforts for other neurological conditions, and modulators of serotonergic signaling are among the most clinically mature tools in neuropsychiatry. Translating the mouse findings to humans will require caution—rodent gestation differs from human pregnancy in important hormonal and neuroanatomical respects, and optogenetics cannot be applied to patients—but the logic of the circuit suggests that restoring serotonergic tone, or dampening SK3 activity, might temper pathological cravings without suppressing the healthy appetite increase that pregnancy demands.

Beyond the clinical horizon, the study reframes a familiar human experience. The sudden, almost gravitational attraction to sweets and fats that so many pregnant women describe may not be a psychological weakness or a trivial side effect of hormonal flux, but the output of a precisely engineered neural adaptation—one that evolution may have favored to ensure developing offspring receive energy-dense nutrition. As Zhao, Feng, Dong, and their colleagues demonstrate, that adaptation can be traced to the opening probability of a potassium pore in a handful of brainstem neurons, and it can be switched on in a non-pregnant brain by forcing that pore open, or switched off in a pregnant one by deleting the gene that builds it. Few stories in modern neuroscience connect a molecule, a circuit, and a deeply human behavior so cleanly. The next chapter—determining whether the same serotonergic brake governs cravings in pregnant women, and whether it can be safely tuned—will be watched closely by neuroscientists, obstetricians, and anyone who has ever wondered why the pickle jar suddenly seems irresistible.

Subject of Research: Serotonin neuron control of pregnancy-induced food craving behavior via SK3 ion channels

Article Title: Serotonin neurons in the dorsal raphe control food-craving-like behavior during pregnancy in mice

Article References: Zhao, Q., Feng, B., Dong, V., Lau, L. H., Liu, H., Yu, M., Liang, K., Tran, C., Feng, H., Smiley, T., Gao, P., Yan, A., Ye, H., Jiang, Y., Wang, C., Xu, P., & He, Y. (2026). Serotonin neurons in the dorsal raphe control food-craving-like behavior during pregnancy in mice. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02445-3

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02445-3

Keywords: serotonin neurons, dorsal raphe nucleus, food cravings, pregnancy, SK3 ion channel, ventral tegmental area, mice study, Nature Neuroscience, maternal obesity, neuroscience, appetite regulation, reward circuitry